Floatz logo

cgt4859

Intrahepatic Cholangiocarcinoma (Icc)

Cogent Biosciences, Inc.Phase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma (Icc) cohort.

Asset / SponsorPhaseRating
Durvalumab
West China Hospital
Phase 2BB
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai 6th People's Hospital
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B

View all 50 →

Same molecule, other indications

cgt4859 is also rated in:

Other Solid Tumors, AdultDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR2 Gene Fusion/RearrangementDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR2 Gene AmplificationDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →